2. Signaling Pathways
  3. GPCR/G Protein
    Neuronal Signaling
  4. Neuropeptide Y Receptor
  5. Neuropeptide Y Receptor Agonist

Neuropeptide Y Receptor Agonist

Neuropeptide Y Receptor Isoform Comparison

Neuropeptide Y Receptor Agonists (57):

Cat. No. Product Name Effect Purity
  • HY-P1128
    Galanin (swine)
    		Agonist 98.99%
    Galanin (swine), a neuropeptide, consists of 29 amino acids and contains a C-terminal amidated glycine. Galanin (swine) inhibits basal and stimulated insulin secretion both in vivo and in vitro under a variety of experimental conditions. Galanin (swine) is a galanin receptor agonist with pKis of 9.63, 9.49, 9.02, 8.98, 8.01 and 8.14 at human GAL1, rat GAL1, human GAL2, rat GAL2, human GAL3 and rat GAL3 respectively.
  • HY-P4060A
    Pancreatic polypeptide TFA
    		Agonist 99.47%
    Pancreatic polypeptide TFA is a neuropeptide Y (NPY) Y4/Y5 receptor agonist.
  • HY-P10545
    [D-His26]-Neuropeptide Y, human, rat
    		Agonist
    [D-His26]-Neuropeptide Y, human, rat is a synthetic variant of neuropeptide Y (NPY). [D-His26]-Neuropeptide Y, human, rat acts as a Y1R agonist that can prevent the development of anxiety, social impairment, and depressive symptoms, and has the potential to be used as an early intervention treatment for post-traumatic stress reactions.
  • HY-P1127
    Galanin (1-30), human
    		Agonist 99.90%
    Galanin (1-30), human is a 30-amino acid neuropeptide, and acts as an agonist of GalR1 and GalR2 receptors, with Kis of both 1 nM.
  • HY-P1723
    Spexin
    		Agonist 98.69%
    Spexin is a conserved peptide plays roles of neurotransmitter/neuromodulator and endocrine factor. Spexin peptide contains numerous aromatic amino acids and is probably amidated.
  • HY-P1323A
    [Leu31,Pro34]-Neuropeptide Y(human,rat,mouse) TFA
    		Agonist 98.07%
    [Leu31,Pro34]-Neuropeptide Y(human,rat) TFA is a specific neuropeptide Y Y1 receptor agonist. [Leu31,Pro34]-Neuropeptide Y(human,rat) TFA slao activates Y4, Y5. [Leu31,Pro34]-Neuropeptide Y(human,rat) TFA can increase blood pressure in anesthetized rats and increases food intake.
  • HY-P10000
    Peptide YY (PYY) (3-36), Human
    		Agonist 98.57%
    Peptide YY (PYY) (3-36), Human is an endogenous appetite suppressing peptide. Peptide YY (PYY) (3-36), Human, a neuropeptide Y (NPY) Y2 receptor agonist, is a powerful inhibitor of intestinal secretion.
  • HY-P0208
    [Leu31,Pro34]-Neuropeptide Y (porcine)
    		Agonist 98.40%
    [Leu31,Pro34]- Neuropeptide Y (porcine), a Neuropeptide Y (NPY) analog, is a selective NPY Y1 receptor agonist. [Leu31,Pro34]- Neuropeptide Y (porcine) exhibits anxiolytic effects.
  • HY-103536A
    Galnon TFA
    		Agonist 99.15%
    Galnon TFA is a selective and non-peptide agonist of galanin GAL1 and GAL2 receptor, with Kis of 11.7 and 34.1 μM respectively. Galnon TFA exhibits anticonvulsant and anxiolytic effects.
  • HY-P2543
    Neuropeptide Y (3-36) (human, rat)
    		Agonist
    Neuropeptide Y (3-36) (human, rat), a neuropeptide Y (NPY) metabolite formed from dipeptidyl peptidase-4 (DPP4), is a selective Y2 receptor agonist. Neuropeptide Y (3-36) (human, rat) is a NPY metabolite formed from dipeptidyl peptidase-4 (DPP4). Neuropeptide Y (3-36) (human, rat) decreases release of norepinephrine via the Y2 receptor.
  • HY-P1021A
    Peptide YY (PYY) (3-36), porcine TFA
    		Agonist 98.17%
    Peptide YY (PYY) (3-36), porcine TFA is a gut hormone peptide that acts as a Y2 receptor agonist to reduce appetite.
  • HY-P0199
    Pancreatic Polypeptide, human
    		Agonist 99.58%
    Pancreatic Polypeptide, human is a C-terminally amidated 36 amino acid peptide, which acts as a neuropeptide Y (NPY) Y4/Y5 receptor agonist.
  • HY-P1131
    M617
    		Agonist 99.54%
    M617 is a selective galanin receptor 1 (GAL1) agonist, with Kis of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiac muscle of type 2 diabetic rats.
  • HY-P1135
    M1145
    		Agonist 99.54%
    M1145, a chimeric peptide, is a selective galanin receptor type 2 (GAL2) agonist, with a Ki of 6.55 nM. M1145 shows more than 90-fold higher affinity for GAL2 over GAL1 (Ki=587 nM) and a 76-fold higher affinity over GalR3 (Ki=497 nM). M1145 has an additive effect on the signal transduction of galanin.
  • HY-P1437
    Neuropeptide S (mouse)
    		Agonist 98.83%
    Neuropeptide S (mouse) is a bioactive peptide. Neuropeptide S (mouse), as a neurotransmitter/neuromodulator of 20 amino acids, can be used for the research of arousal, anxiety, locomotion, feeding behaviors, memory and agent addiction.
  • HY-P1250
    RFRP-3(human)
    		Agonist 99.21%
    RFRP-3 (Neuropeptide VF(124-131))(human), a human GnIH peptide homolog, is a potent inhibitor of gonadotropin secretion by inhibiting Ca2+?mobilization. RFRP-3(human) is a NPFF1?receptor agonist, it inhibits forskolin-induced production of cAMP with an IC50 of 0.7 nM.
  • HY-P1428
    RFRP-1(human)
    		Agonist 99.67%
    RFRP-1(human) is a gonadotropin-inhibitory hormone (GnIH) homolog. RFRP-1(human) targets human gonadotropin-releasing hormone (GnRH) neurons and gonadotropes and potently inhibits gonadotropin. RFRP-1(human) is a potent Neuropeptide FF (NPFF) receptor agonist with EC50s of 0.0011 nM and 29 nM for NPFF2 and NPFF1, respectively.
  • HY-P1480
    Neuropeptide Y (13-36), amide, human
    		Agonist 98.48%
    Neuropeptide Y (13-36), amide, human is a selective neuropeptide Y2 receptor agonist.
  • HY-P1324
    [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide
    		Agonist 99.25%
    [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide is a potent and selective neuropeptide Y Y5 receptor agonist with an IC50 of 0.24 nM for binding to the hY5 receptor. [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide induces a high amount of food intake.
  • HY-P1132A
    Galanin (1-29)(rat, mouse) TFA
    		Agonist 99.67%
    Galanin (1-29)(rat, mouse) TFA is a non-selective galanin receptor agonist, with Kis of 0.98, 1.48 and 1.47 nM for GAL1, GAL2 and GAL3, respectively. Anticonvulsant effect.